☰

Natalia A. Ignatenko - Publications

Affiliations: 
Cancer Biology University of Arizona, Tucson, AZ 
Area:
Molecular Biology, Cell Biology, Oncology
Tree Info Grants Similar researchers PubMed Report error

39 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Bouzid H, Soualmia F, Oikonomopoulou K, Soosaipillai A, Walker F, Louati K, Lo Dico R, Pocard M, El Amri C, Ignatenko NA, Darmoul D. Kallikrein-Related Peptidase 6 (KLK6) as a Contributor toward an Aggressive Cancer Cell Phenotype: A Potential Role in Colon Cancer Peritoneal Metastasis. Biomolecules. 12. PMID 35883559 DOI: 10.3390/biom12071003  0.368
2021 Pandey R, Zhou M, Chen Y, Darmoul D, Kisiel CC, Nfonsam VN, Ignatenko NA. Molecular Pathways Associated with Kallikrein 6 Overexpression in Colorectal Cancer. Genes. 12. PMID 34065672 DOI: 10.3390/genes12050749  0.34
2019 Chen H, Sells E, Pandey R, Abril ER, Hsu CH, Krouse RS, Nagle RB, Pampalakis G, Sotiropoulou G, Ignatenko NA. Kallikrein 6 protease advances colon tumorigenesis induction of the high mobility group A2 protein. Oncotarget. 10: 6062-6078. PMID 31692974 DOI: 10.18632/Oncotarget.27153  0.48
2019 De Vita E, Smits N, van den Hurk H, Beck EM, Hewitt J, Baillie G, Russell E, Pannifer A, Hamon V, Morrison A, McElroy SP, Jones P, Ignatenko N, Gunkel N, Miller AK. Synthesis and structure-activity relationships of N-(4-benzamidino)-oxazolidinones-potent and selective inhibitors of kallikrein-related peptidase 6. Chemmedchem. PMID 31675166 DOI: 10.1002/Cmdc.201900536  0.306
2017 Rice PFS, Ehrichs KG, Jones MS, Chen H, Hsu CH, Abril ER, Nagle RB, Besselsen DG, Barton JK, Ignatenko NA. Does mutated K-RAS oncogene attenuate the effect of Sulindac in colon cancer chemoprevention? Cancer Prevention Research (Philadelphia, Pa.). PMID 29118162 DOI: 10.1158/1940-6207.Capr-17-0230  0.386
2017 Sells E, Pandey R, Chen H, Skovan BA, Cui H, Ignatenko NA. Specific microRNA-mRNA Regulatory Network of Colon Cancer Invasion Mediated by Tissue Kallikrein-Related Peptidase 6. Neoplasia (New York, N.Y.). 19: 396-411. PMID 28431272 DOI: 10.1016/J.Neo.2017.02.003  0.368
2017 Chen H, Sells E, Cui H, Pandey R, Pampalakis G, Sotiropoulou G, Doetschman T, Ignatenko NA. Abstract 854: Human tissue Kallikrein 6 enzyme activity regulates epithelial-mesenchymal transition in colon cancer Cancer Research. 77: 854-854. DOI: 10.1158/1538-7445.Am2017-854  0.39
2015 Padavano J, Henkhaus RS, Chen H, Skovan BA, Cui H, Ignatenko NA. Mutant K-RAS Promotes Invasion and Metastasis in Pancreatic Cancer Through GTPase Signaling Pathways. Cancer Growth and Metastasis. 8: 95-113. PMID 26512205 DOI: 10.4137/CGM.S29407  0.312
2015 Roy UKB, Henkhaus RS, Loupakis F, Cremolini C, Gerner EW, Ignatenko NA. Erratum: Caveolin-1 is a novel regulator of K-RASdependent migration in colon carcinogenesis (International Journal of Cancer (2013) 133: 1 (43-57) DOI: 10.1002/ijc.28001) International Journal of Cancer. 137. PMID 26252817 DOI: 10.1002/Ijc.29624  0.381
2014 Skovan BA, Pandey R, Nagle RB, Cui H, Buckmeier JA, Krouse RS, Thompson PA, Ignatenko NA. Abstract 2009: Role of kallikrein 6 secretion in metastatic colon cancer Cancer Research. 74: 2009-2009. DOI: 10.1158/1538-7445.Am2014-2009  0.478
2014 Cantoria MJ, Boros LG, Patel H, Han H, Ignatenko N, Meuillet EJ. Abstract 1434: Metformin-induced metabolic changes are k-ras-dependent in animal models of pancreatic cancer Cancer Research. 74: 1434-1434. DOI: 10.1158/1538-7445.Am2014-1434  0.423
2013 Ignatenko NA, Gerner EW. Get the fat out! Cancer Prevention Research (Philadelphia, Pa.). 6: 161-4. PMID 23466814 DOI: 10.1158/1940-6207.Capr-13-0025  0.324
2013 Basu Roy UK, Henkhaus RS, Loupakis F, Cremolini C, Gerner EW, Ignatenko NA. Caveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis. International Journal of Cancer. 133: 43-57. PMID 23280667 DOI: 10.1002/Ijc.28001  0.4
2011 Paz EA, Garcia-Huidobro J, Ignatenko NA. Polyamines in cancer. Advances in Clinical Chemistry. 54: 45-70. PMID 21874756 DOI: 10.1016/B978-0-12-387025-4.00002-9  0.431
2011 Ignatenko NA, Gerner EW, Besselsen DG. Defining the role of polyamines in colon carcinogenesis using mouse models. Journal of Carcinogenesis. 10: 10. PMID 21712957 DOI: 10.4103/1477-3163.79673  0.421
2009 Zell JA, Ziogas A, Ignatenko N, Honda J, Qu N, Bobbs AS, Neuhausen SL, Gerner EW, Anton-Culver H. Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 6208-16. PMID 19789310 DOI: 10.1158/1078-0432.Ccr-09-0592  0.395
2008 Ignatenko NA, Besselsen DG, Stringer DE, Blohm-Mangone KA, Cui H, Gerner EW. Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis. Nutrition and Cancer. 60: 30-5. PMID 19003578 DOI: 10.1080/01635580802401317  0.405
2008 Henkhaus RS, Gerner EW, Ignatenko NA. Kallikrein 6 is a mediator of K-RAS-dependent migration of colon carcinoma cells. Biological Chemistry. 389: 757-64. PMID 18627290 DOI: 10.1515/Bc.2008.087  0.433
2008 Roy UK, Henkhaus RS, Ignatenko NA, Mora J, Fultz KE, Gerner EW. Wild-type APC regulates caveolin-1 expression in human colon adenocarcinoma cell lines via FOXO1a and C-myc. Molecular Carcinogenesis. 47: 947-55. PMID 18444242 DOI: 10.1002/Mc.20451  0.441
2008 Ignatenko NA, Gerner EW. HuRrying colon cancer progression. Cancer Biology & Therapy. 7: 428-9. PMID 18285701 DOI: 10.4161/Cbt.7.3.5583  0.33
2008 Henkhaus RS, Roy UK, Cavallo-Medved D, Sloane BF, Gerner EW, Ignatenko NA. Caveolin-1-mediated expression and secretion of kallikrein 6 in colon cancer cells. Neoplasia (New York, N.Y.). 10: 140-8. PMID 18283336 DOI: 10.1593/Neo.07817  0.448
2007 Hariri LP, Qiu Z, Tumlinson AR, Besselsen DG, Gerner EW, Ignatenko NA, Povazay B, Hermann B, Sattmann H, McNally J, Unterhuber A, Drexler W, Barton JK. Serial endoscopy in azoxymethane treated mice using ultra-high resolution optical coherence tomography. Cancer Biology & Therapy. 6: 1753-62. PMID 17986850 DOI: 10.1117/12.699249  0.326
2007 Bernstein H, Holubec H, Bernstein C, Ignatenko NA, Gerner E, Dvorak K, Besselsen D, Blohm-Mangone KA, Padilla-Torres J, Dvorakova B, Garewal H, Payne CM. Deoxycholate-induced colitis is markedly attenuated in Nos2 knockout mice in association with modulation of gene expression profiles. Digestive Diseases and Sciences. 52: 628-42. PMID 17253130 DOI: 10.1007/S10620-006-9608-0  0.37
2007 Zell JA, Ignatenko NA, Yerushalmi HF, Ziogas A, Besselsen DG, Gerner EW, Anton-Culver H. Risk and risk reduction involving arginine intake and meat consumption in colorectal tumorigenesis and survival. International Journal of Cancer. 120: 459-68. PMID 17096347 DOI: 10.1002/Ijc.22311  0.396
2006 Ignatenko NA, Besselsen DG, Roy UK, Stringer DE, Blohm-Mangone KA, Padilla-Torres JL, Guillen-R JM, Gerner EW. Dietary putrescine reduces the intestinal anticarcinogenic activity of sulindac in a murine model of familial adenomatous polyposis. Nutrition and Cancer. 56: 172-81. PMID 17474863 DOI: 10.1207/S15327914Nc5602_8  0.419
2006 Ignatenko NA, Yerushalmi HF, Watts GS, Futscher BW, Stringer DE, Marton LJ, Gerner EW. Pharmacogenomics of the polyamine analog 3,8,13,18-tetraaza-10,11-[(E)-1,2-cyclopropyl]eicosane tetrahydrochloride, CGC-11093, in the colon adenocarcinoma cell line HCT1161. Technology in Cancer Research & Treatment. 5: 553-64. PMID 17121431 DOI: 10.1177/153303460600500602  0.347
2006 Ignatenko NA, Holubec H, Besselsen DG, Blohm-Mangone KA, Padilla-Torres JL, Nagle RB, de Alboránç IM, Guillen-R JM, Gerner EW. Role of c-Myc in intestinal tumorigenesis of the ApcMin/+ mouse. Cancer Biology & Therapy. 5: 1658-64. PMID 17106247 DOI: 10.4161/Cbt.5.12.3376  0.386
2006 Yerushalmi HF, Besselsen DG, Ignatenko NA, Blohm-Mangone KA, Padilla-Torres JL, Stringer DE, Guillen JM, Holubec H, Payne CM, Gerner EW. Role of polyamines in arginine-dependent colon carcinogenesis in Apc(Min) (/+) mice. Molecular Carcinogenesis. 45: 764-73. PMID 16705737 DOI: 10.1002/Mc.20246  0.422
2006 Bernstein H, Holubec H, Bernstein C, Ignatenko N, Gerner E, Dvorak K, Besselsen D, Ramsey L, Dall'Agnol M, Blohm-Mangone KA, Padilla-Torres J, Cui H, Garewal H, Payne CM. Unique dietary-related mouse model of colitis. Inflammatory Bowel Diseases. 12: 278-93. PMID 16633050 DOI: 10.1097/01.Mib.0000209789.14114.63  0.39
2006 Yerushalmi HF, Besselsen DG, Ignatenko NA, Blohm-Mangone KA, Padilla-Torres JL, Stringer DE, Cui H, Holubec H, Payne CM, Gerner EW. The role of NO synthases in arginine-dependent small intestinal and colonic carcinogenesis. Molecular Carcinogenesis. 45: 93-105. PMID 16329147 DOI: 10.1002/Mc.20168  0.425
2005 Gerner EW, Ignatenko NA, Lance P, Hurley LH. A comprehensive strategy to combat colon cancer targeting the adenomatous polyposis coli tumor suppressor gene. Annals of the New York Academy of Sciences. 1059: 97-105. PMID 16382048 DOI: 10.1196/Annals.1339.033  0.46
2004 Ignatenko NA, Zhang H, Watts GS, Skovan BA, Stringer DE, Gerner EW. The chemopreventive agent alpha-difluoromethylornithine blocks Ki-ras-dependent tumor formation and specific gene expression in Caco-2 cells. Molecular Carcinogenesis. 39: 221-33. PMID 15057874 DOI: 10.1002/Mc.20008  0.398
2004 Ignatenko NA, Babbar N, Mehta D, Casero RA, Gerner EW. Suppression of polyamine catabolism by activated Ki-ras in human colon cancer cells. Molecular Carcinogenesis. 39: 91-102. PMID 14750214 DOI: 10.1002/Mc.10166  0.389
2003 Babbar N, Ignatenko NA, Casero RA, Gerner EW. Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer. The Journal of Biological Chemistry. 278: 47762-75. PMID 14506281 DOI: 10.1074/Jbc.M307265200  0.45
2003 Gerner EW, Ignatenko NA, Besselsen DG. Preclinical models for chemoprevention of colon cancer. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. ProgrèS Dans Les Recherches Sur Le Cancer. 163: 58-71; discussion 26. PMID 12903843 DOI: 10.1007/978-3-642-55647-0_6  0.428
2003 Martinez JD, Parker MT, Fultz KE, Ignatenko NA, Gerner EW. Molecular Biology of Cancer Burger's Medicinal Chemistry and Drug Discovery. 1-50. DOI: 10.1002/0471266949.Bmc074  0.407
2002 Gerner EW, Ignatenko NA, Besselsen DG. Session 4 S9. Genetically altered rodents and human tumor cells as preclinical models for prevention of intestinal cancers European Journal of Cancer. 38: S12. DOI: 10.1016/S0959-8049(02)80617-7  0.41
1999 Erdman SH, Ignatenko NA, Powell MB, Blohm-Mangone KA, Holubec H, Guillén-Rodriguez JM, Gerner EW. APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse. Carcinogenesis. 20: 1709-13. PMID 10469614 DOI: 10.1093/Carcin/20.9.1709  0.441
1991 Berdinskikh NK, Ignatenko NA, Zaletok SP, Ganina KP, Chorniy VA. Ornithine decarboxylase activity and polyamine content in adenocarcinomas of human stomach and large intestine International Journal of Cancer. 47: 496-498. PMID 1995479 DOI: 10.1002/Ijc.2910470404  0.36
Show low-probability matches.